Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How? On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?Prof. Gerhardt Attard, Assoc. Prof. Tanya Dorff, Prof. Fred Saad
Take the e-learning and claim your CME credit. Watch the video and download the slides.
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Prof. Fred Saad
Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center, Canada
Canada
| 
60 min
|accreditation:
EACCME |
Mar 2022
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Targeting Advanced Prostate Cancer with PARP inhibitors: Who, When and How?
- The efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour types
- Implementation of testing strategies to predict if the prostate cancer is likely to respond to a PARP inhibitor or some other treatment
- Data of combination studies with PARP inhibitors, the appropriate implementation in treatment strategies and the impact on clinical practice
Take the e-learning and claim your CME credit.
Watch the Experts Knowledge Share event and download the slides above.
Meeting Video Chapters
| Chapter 1 | 00:00 | Faculty and Disclaimer |
| Chapter 2 | 00:28 | Overview and scene-setting - Prof. Fred Saad |
| Chapter 3 | 02:08 | Who should you treat? - Prof. Gerhardt Attard |
| Chapter 4 | 18:55 | Why you should treat - Assoc. Prof. Tanya Dorff |
| Chapter 5 | 33:11 | Combination therapy with PARP inhibitors - Prof. Fred Saad |
| Chapter 6 | 46:48 | Questions for panel |
| Chapter 7 | 52:13 | Future perspectives and summary - Prof Fred Saad |
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Prof. Gerhardt Attard
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Other programmes developed by Assoc. Prof. Tanya Dorff
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
